Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Sanofi to buy natural killer cell company Kiadis

by Ryan Cross
November 8, 2020 | A version of this story appeared in Volume 98, Issue 43

 

Sanofi has made an offer to purchase the cell therapy company Kiadis Pharma for about $358 million. Kiadis uses CRISPR gene editing to knock out or insert genes in immune cells called natural killer cells. The firm is testing these cells in early clinical and preclinical programs as treatments for cancer and infectious diseases, including COVID-19. In July, Sanofi licensed rights to one Kiadis cell therapy that the firms hope to test in people with multiple myeloma alongside Sanofi’s recently approved antibody drug Sarclisa.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.